The PartoSure Test is a rapid, non-invasive strip test for the detection of placental alpha microglobulin-1 (PAMG-1) in patients presenting with signs and symptoms of preterm labour.

  • PartoSure’s unique features include:
  • High Positive (PPV) and Negative Predictive Value (NPV)
  • Usable shortly after vaginal exam
  • Speculum examination optional
  • Results in 5 minutes or less
  • No special equipment or training needed
  • Wide gestational age range from 20 to 36 week and six days


The European Association of Perinatal Medicine published its updated Preterm Labor and Birth Management Guidelines in 2017, and the PartoSure test’s placental alpha-microglobulin-1 (PAMG-1) was identified as the biomarker test with the highest combination of negative predictive value (NPV) and positive predictive value (PPV) to be used in women with equivocal cervical length measurements between 15 and 30 mm.

A recent large scale meta-analysis comparing PartoSure with all other biomarkers confirms that the PAMG-1 test was found to have the highest PPV and LR+ (Positive Likelihood Ratio) across all risk stratification groups with statistical significance.
Published studies suggest a lower rate of false positive test results and associated higher PPVs, such as those seen in the PartoSure Test, may contribute to:

  • Decreasing unnecessary admissions
  • More judicious use of therapeutic interventions, such as corticosteroids and tocolytic agents
  • Reducing the length of stay of high risk patients
  • Minimizing unnecessary in-utero transfers to tertiary care centres
  • Given the potential of a positive biomarker test to influence the decision to admit and/or treat, the PartoSure test leads to reductions in unnecessary hospitalizations and in-utero transfers to tertiary care centres and allows for more judicious use of therapeutic interventions, such as antenatal corticosteroids and tocolytic agents.
  • Decrease costs compared to other biomarkers